On November 5, 2013, Depomed, Inc. (DEPO) reported financial results for the third quarter ended September 30, 2013. Total revenues in the quarter were $37.5 million, comprised of $16.3 million in product sales, $15.4 million in royalties, and $5.8 million in licensing and collaborative fees. The breakdown of revenues for each line item can be seen below:
Gross margin in the quarter was an impressive 95.3%. Operating expenses were primarily driven by sales, general and administrative (SG&A) costs of $26.4 million. This was right in line with our forecast. R&D cost totaled only $1.3 million in the quarter, as the company has no active clinical programs. Net income for the quarter totaled $6.5 million, or $0.11 per...
Only subscribers can access this article, which is part of the PRO research library covering 3,570 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: